Literature DB >> 21439442

Natural history of multiple sclerosis: long-term prognostic factors.

Christel Renoux1.   

Abstract

Several prognostic factors of long-term irreversible disability, mainly demographic and clinical, have been described in multiple sclerosis (MS). Most predictors have a minor influence on the long-term prognosis, and efforts are currently shifting toward finding relevant paraclinical predictors. By contrast, the study of prognostic factors has given some insights into the pathogenesis of MS, notably regarding the relation between relapses and long-term disability, and has emphasized the need to elucidate the exact mechanisms underlying neurodegeneration for the development of new therapeutic targets.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21439442     DOI: 10.1016/j.ncl.2011.01.006

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  12 in total

1.  Elevated plasma homocysteine levels are associated with disability progression in patients with multiple sclerosis.

Authors:  Sayonara Rangel Oliveira; Tamires Flauzino; Beatriz Sardinha Sabino; Ana Paula Kallaur; Daniela Frizon Alfieri; Damacio Ramon Kaimen-Maciel; Helena Kaminami Morimoto; Elaine Regina Delicato de Almeida; Marcell Alysson Batisti Lozovoy; Edna Maria Vissoci Reiche; Isaias Dichi; Andréa Name Colado Simão
Journal:  Metab Brain Dis       Date:  2018-05-24       Impact factor: 3.584

2.  Multiple sclerosis: preventing progression and disability in MS-when to treat?

Authors:  Maura Pugliatti
Journal:  Nat Rev Neurol       Date:  2013-02-19       Impact factor: 42.937

3.  Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study.

Authors:  Amit Bar-Or; Ralf Gold; Ludwig Kappos; Douglas L Arnold; Gavin Giovannoni; Krzysztof Selmaj; John O'Gorman; Monica Stephan; Katherine T Dawson
Journal:  J Neurol       Date:  2013-09       Impact factor: 4.849

4.  Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study.

Authors:  Michael Hutchinson; Robert J Fox; David H Miller; J Theodore Phillips; Mariko Kita; Eva Havrdova; John O'Gorman; Ray Zhang; Mark Novas; Vissia Viglietta; Katherine T Dawson
Journal:  J Neurol       Date:  2013-06-08       Impact factor: 4.849

5.  Factors Associated with Poor Sleep in Older Adults with Multiple Sclerosis.

Authors:  Sheila N Garland; Samantha R M Scurrey; Michelle Ploughman
Journal:  Int J Behav Med       Date:  2017-12

6.  FutureMS cohort profile: a Scottish multicentre inception cohort study of relapsing-remitting multiple sclerosis.

Authors:  Patrick K A Kearns; Sarah J Martin; Jessie Chang; Rozanna Meijboom; Elizabeth N York; Yingdi Chen; Christine Weaver; Amy Stenson; Katarzyna Hafezi; Stacey Thomson; Elizabeth Freyer; Lee Murphy; Adil Harroud; Peter Foley; David Hunt; Margaret McLeod; Jonathon O'Riordan; F J Carod-Artal; Niall J J MacDougall; Sergio E Baranzini; Adam D Waldman; Peter Connick; Siddharthan Chandran
Journal:  BMJ Open       Date:  2022-06-29       Impact factor: 3.006

7.  Clinical and demographic factors affecting disease severity in patients with multiple sclerosis.

Authors:  Somayeh Baghizadeh; Mohammad Ali Sahraian; Nahid Beladimoghadam
Journal:  Iran J Neurol       Date:  2013

8.  Glial pathology and retinal neurotoxicity in the anterior visual pathway in experimental autoimmune encephalomyelitis.

Authors:  Jing Jin; Matthew D Smith; Calvin J Kersbergen; Tae-In Kam; Mayuri Viswanathan; Kyle Martin; Ted M Dawson; Valina L Dawson; Donald J Zack; Katharine Whartenby; Peter A Calabresi
Journal:  Acta Neuropathol Commun       Date:  2019-07-31       Impact factor: 7.801

9.  Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.

Authors:  H Tedeholm; J Lycke; B Skoog; V Lisovskaja; J Hillert; C Dahle; J Fagius; S Fredrikson; A-M Landtblom; C Malmeström; C Martin; F Piehl; B Runmarker; L Stawiarz; M Vrethem; O Nerman; O Andersen
Journal:  Mult Scler       Date:  2012-11-01       Impact factor: 6.312

10.  Exploring the predictive value of the evoked potentials score in MS within an appropriate patient population: a hint for an early identification of benign MS?

Authors:  Nicolò Margaritella; Laura Mendozzi; Massimo Garegnani; Raffaello Nemni; Elena Colicino; Elisabetta Gilardi; Luigi Pugnetti
Journal:  BMC Neurol       Date:  2012-08-22       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.